- Home
- MMT vs PROK Comparison
MMT vs PROK Comparison
Compare MMT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMT
- PROK
- Stock Information
- Founded
- MMT 1987
- PROK 2015
- Country
- MMT United States
- PROK United States
- Employees
- MMT N/A
- PROK N/A
- Industry
- MMT Trusts Except Educational Religious and Charitable
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MMT Finance
- PROK Health Care
- Exchange
- MMT Nasdaq
- PROK Nasdaq
- Market Cap
- MMT 270.5M
- PROK 271.2M
- IPO Year
- MMT N/A
- PROK N/A
- Fundamental
- Price
- MMT $4.80
- PROK $1.81
- Analyst Decision
- MMT
- PROK Buy
- Analyst Count
- MMT 0
- PROK 5
- Target Price
- MMT N/A
- PROK $4.50
- AVG Volume (30 Days)
- MMT 86.5K
- PROK 509.0K
- Earning Date
- MMT 01-01-0001
- PROK 11-12-2024
- Dividend Yield
- MMT 8.58%
- PROK N/A
- EPS Growth
- MMT N/A
- PROK N/A
- EPS
- MMT 0.30
- PROK N/A
- Revenue
- MMT N/A
- PROK N/A
- Revenue This Year
- MMT N/A
- PROK N/A
- Revenue Next Year
- MMT N/A
- PROK N/A
- P/E Ratio
- MMT $15.33
- PROK N/A
- Revenue Growth
- MMT N/A
- PROK N/A
- 52 Week Low
- MMT $4.04
- PROK $1.12
- 52 Week High
- MMT $4.70
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- MMT 37.80
- PROK 47.38
- Support Level
- MMT $4.84
- PROK $1.83
- Resistance Level
- MMT $4.89
- PROK $1.90
- Average True Range (ATR)
- MMT 0.03
- PROK 0.16
- MACD
- MMT -0.01
- PROK 0.04
- Stochastic Oscillator
- MMT 0.00
- PROK 72.55
About MMT MFS Multimarket Income Trust
MFS Multimarket Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests a majority of its net assets in fixed-income securities, corporate bonds of the U.S and foreign issuers, U.S Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S and foreign issuers, and debt instruments of issuers located in emerging market countries. The portfolio of investments comprises of different sector investments such as aerospace, airlines, automotive, chemicals, electronics, and others.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.